Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

Leukemia

Volumn 28, Issue 11, 2014, Pages 2188-2196

  Herman, S E M ^a   Niemann, C U ^a   Farooqui, M ^a   Jones, J ^a,b   Mustafa, R Z ^a   Lipsky, A ^a   Saba, N ^a   Martyr, S ^a   Soto, S ^a   Valdez, J ^a   Gyamfi, J A ^a   Maric, I ^c   Calvo, K R ^c   Pedersen, L B ^d   Geisler, C H ^d   Liu, D ^a   Marti, G E ^a   Aue, G ^a   Wiestner, A ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IBRUTINIB; LYMPHOCYTE ANTIGEN RECEPTOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

AGED; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BLOOD; BLOOD VISCOSITY; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; HUMAN; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MALE; METABOLISM; PHASE 2 CLINICAL TRIAL; SIGNAL TRANSDUCTION; TUMOR VOLUME;

AGED; BLOOD VISCOSITY; FEMALE; HEMOGLOBINS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MALE; MODELS, BIOLOGICAL; PYRAZOLES; PYRIMIDINES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; TUMOR BURDEN;

EID: 84922322355     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.122     Document Type: Article

References (52)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804–815. DOI: 10.1056/NEJMra041720
2. NIH. NCI Surveillance Epidemiology and End Results. Department of Health & Human Services: Bethesda, MD, USA, 2012, seer.cancer.gov.
3. Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population-based data. J Natl Cancer Inst 2010; 102: 1584–1598. DOI: 10.1093/jnci/djq366
4. Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007; 109: 4679–4685. DOI: 10.1182/blood-2005-12-051458
5. Rosenquist R, Cortese D, Bhoi S, Mansouri L, Gunnarsson R. Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand? Leuk Lymphoma 2013; 54: 2351–2364. DOI: 10.3109/10428194.2013.783913
6. Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011; 118: 4313–4320. DOI: 10.1182/blood-2011-06-338855
7. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 2012; 120: 4684–4691. DOI: 10.1182/blood-2012-05-423194
8. Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012; 120: 1175–1184. DOI: 10.1182/blood-2012-02-362624
9. Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, Allen SL et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998; 102: 1515–1525. DOI: 10.1172/JCI3009
10. Tobin G, Thunberg U, Karlsson K, Murray F, Laurell A, Willander K et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 2004; 104: 2879–2885. DOI: 10.1182/blood-2004-01-0132
11. Messmer BT, Albesiano E, Efremov DG, Ghiotto F, Allen SL, Kolitz J et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004; 200: 519–525. DOI: 10.1084/jem.20040544
12. Agathangelidis A, Darzentas N, Hadzidimitriou A, Brochet X, Murray F, Yan XJ et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 2012; 119: 4467–4475. DOI: 10.1182/blood-2011-11-393694
13. Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011; 117: 563–574. DOI: 10.1182/blood-2010-05-284984
14. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009; 114: 3367–3375. DOI: 10.1182/blood-2009-06-225326
15. Niemann CU, Wiestner A. B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol 2013; 23: 410–421. DOI: 10.1016/j.semcancer.2013.09.001
16. Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013; 12: 229–243. DOI: 10.1038/nrd3937
17. Buggy JJ, Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol 2012; 31: 119–132. DOI: 10.3109/08830185.2012.664797
18. Humphries LA, Dangelmaier C, Sommer K, Kipp K, Kato RM, Griffith N et al. Tec kinases mediate sustained calcium influx via site-specific tyrosine phosphorylation of the phospholipase Cgamma Src homology 2-Src homology 3 linker. J Biol Chem 2004; 279: 37651–37661. DOI: 10.1074/jbc.M311985200
19. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88–92. DOI: 10.1038/nature08638
20. Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA et al. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood 2013; 123: 1207–1213. DOI: 10.1182/blood-2013-07-515361
21. Kil LP, de Bruijn MJ, van Hulst JA, Langerak AW, Yuvaraj S, Hendriks RW. Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia. Am J Blood Res 2013; 3: 71–83.
22. Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. Chem Med Chem 2007; 2: 58–61. DOI: 10.1002/cmdc.200600221
23. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88–94. DOI: 10.1200/JCO.2012.42.7906
24. Wiestner A. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 2013; 31: 128–130. DOI: 10.1200/JCO.2012.44.4281
25. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32–42. DOI: 10.1056/NEJMoa1215637
26. Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011; 117: 6287–6296. DOI: 10.1182/blood-2011-01-328484
27. de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012; 119: 2590–2594. DOI: 10.1182/blood-2011-11-390989
28. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012; 119: 1182–1189. DOI: 10.1182/blood-2011-10-386417
29. de Gorter DJ, Beuling EA, Kersseboom R, Middendorp S, van Gils JM, Hendriks RW et al. Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 2007; 26: 93–104. DOI: 10.1016/j.immuni.2006.11.012
30. Herman SE, Sun X, McAuley EM, Hsieh MM, Pittaluga S, Raffeld M et al. Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy. Leukemia 2013; 27: 1769–1773. DOI: 10.1038/leu.2013.37
31. Davids MS, Brown JR. Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53: 2362–2370. DOI: 10.3109/10428194.2012.695781
32. Cheson BD, Byrd JC, Rai KR, Kay NE, O'Brien SM, Flinn IW et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012; 30: 2820–2822. DOI: 10.1200/JCO.2012.43.3748
33. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115: 2578–2585. DOI: 10.1182/blood-2009-08-236471
34. Zhang B, Lewis SM. The splenomegaly of myeloproliferative and lymphoproliferative disorders: splenic cellularity and vascularity. Eur J Haematol 1989; 43: 63–66. DOI: 10.1111/j.1600-0609.1989.tb01253.x
35. Sambuceti G, Brignone M, Marini C, Massollo M, Fiz F, Morbelli S et al. Estimating the whole bone-marrow asset in humans by a computational approach to integrated PET/CT imaging. Eur J Nucl Med Mol Imaging 2012; 39: 1326–1338. DOI: 10.1007/s00259-012-2141-9
36. Pesic V, Plecas-Solarovic B, Radojevic K, Kosec D, Pilipovic I, Perisic M et al. Long-term beta-adrenergic receptor blockade increases levels of the most mature thymocyte subsets in aged rats. Int Immunopharmacol 2007; 7: 674–686. DOI: 10.1016/j.intimp.2007.01.017
37. Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery 1962; 51: 224–232.
38. Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 2014; 123: 1810–1817. DOI: 10.1182/blood-2013-09-527853
39. Kuse R, Lueb H. Gastrointestinal involvement in patients with chronic lymphocytic leukemia. Leukemia 1997; 11 (Suppl 2): S50–S51.
40. Baumhoer D, Tzankov A, Dirnhofer S, Tornillo L, Terracciano LM. Patterns of liver infiltration in lymphoproliferative disease. Histopathology 2008; 53: 81–90. DOI: 10.1111/j.1365-2559.2008.03069.x
41. Brandtzaeg P, Farstad IN, Johansen FE, Morton HC, Norderhaug IN, Yamanaka T. The B-cell system of human mucosae and exocrine glands. Immunol Rev 1999; 171: 45–87. DOI: 10.1111/j.1600-065X.1999.tb01342.x
42. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005; 115: 755–764. DOI: 10.1172/JCI23409
43. Calissano C, Damle RN, Hayes G, Murphy EJ, Hellerstein MK, Moreno C et al. In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. Blood 2009; 114: 4832–4842. DOI: 10.1182/blood-2009-05-219634
44. Chang BY, Francesco M, De Rooij MF, Magadala P, Steggerda SM, Huang MM et al. Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood 2013; 122: 2412–2424. DOI: 10.1182/blood-2013-02-482125
45. Herman SE, Barr PM, McAuley EM, Liu D, Wiestner A, Friedberg JW. Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. Leukemia 2013; 27: 1769–1773. DOI: 10.1038/leu.2013.37
46. Herman SEM, Farooqui M, Bezabhie R, Aue G, Wiestner A. In vivo effects of ibrutinib on BCR signaling, tumor cell activation and proliferation in blood and tissue-resident cells of chronic lymphocytic leukemia patients. ASH Annu Meeting Abstracts 2012; 120: 185.
47. Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia 2013; 28: 649–657. DOI: 10.1038/leu.2013.358
48. Ganzel C, Becker J, Mintz PD, Lazarus HM, Rowe JM. Hyperleukocytosis, leukostasis and leukapheresis: practice management. Blood Rev 2012; 26: 117–122. DOI: 10.1016/j.blre.2012.01.003
49. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975–980. DOI: 10.1182/blood-2008-02-140582
50. Calissano C, Damle RN, Marsilio S, Yan XJ, Yancopoulos S, Hayes G et al. Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells. Mol Med 2011; 17: 1374–1382. DOI: 10.2119/molmed.2011.00360
51. Cukierman T, Gatt ME, Libster D, Goldschmidt N, Matzner Y. Chronic lymphocytic leukemia presenting with extreme hyperleukocytosis and thrombosis of the common femoral vein. Leuk Lymphoma 2002; 43: 1865–1868. DOI: 10.1080/1042819021000006367
52. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507–516. DOI: 10.1056/NEJMoa1306220